Regen BioPharmaRGBP Receivables Turnover is 0.24 as of Mar. 2026. The stock has 7 warning signs investors should review. Among 843 Biotechnology companies, Regen BioPharma ranks worse than 90.63% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Regen BioPharma's Revenue for the
three
months ended in Mar. 2026 was $0.06 Mil. Regen BioPharma's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0.25 Mil.
Hence, Regen BioPharma's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.24.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Regen BioPharma Receivables Turnover Related Terms
Regen BioPharma Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Regen BioPharma's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RGBP vs SIGY, ENDV, CNBX: Receivables Turnover Comparison
For the Biotechnology subindustry, Regen BioPharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regen BioPharma Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regen BioPharma's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Regen BioPharma's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regen BioPharma (RGBP) has a Receivables Turnover of 0.24 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Regen BioPharma and its competitors. According to the industry distribution chart, Regen BioPharma ranks #764 out of 843 companies in the Biotechnology industry, placing it in the top 90.6%.
Is Regen BioPharma's Receivables Turnover too high?
Regen BioPharma's current Receivables Turnover is 0.24. The Biotechnology industry median Receivables Turnover is 5.28. Regen BioPharma's value of 0.24 is 95.5% below this industry median. Based on the distribution chart, Regen BioPharma ranks #764 out of 843 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Regen BioPharma's Receivables Turnover compare to SIGY and ENDV?
According to the Biotechnology industry distribution chart, Regen BioPharma ranks #764 out of 843 companies for Receivables Turnover. This places Regen BioPharma in the lower half of its industry. The industry median Receivables Turnover is 5.28. Regen BioPharma's value of 0.24 is 95.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 843 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regen BioPharma's current Receivables Turnover of 0.24 is 95.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Regen BioPharma and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regen BioPharma's current Receivables Turnover is 0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regen BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Regen BioPharma (RGBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.00 — trading 99.5% below its estimated fair value. The current Receivables Turnover is 0.24 and 95.5% below the Biotechnology industry median of 5.28. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Regen BioPharma (RGBP), the current Receivables Turnover is 0.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGBP has been successfully added to your 